GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Grace Therapeutics Inc (NAS:GRCE) » Definitions » Revenue

GRCE (Grace Therapeutics) Revenue : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Grace Therapeutics Revenue?

Grace Therapeutics's revenue for the three months ended in Dec. 2024 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil. Grace Therapeutics's Revenue per Share for the three months ended in Dec. 2024 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Grace Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 111.30% per year. The lowest was 111.30% per year. And the median was 111.30% per year.


Grace Therapeutics Revenue Historical Data

The historical data trend for Grace Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grace Therapeutics Revenue Chart

Grace Therapeutics Annual Data
Trend Feb14 Feb15 Feb16 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.20 - - -

Grace Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Grace Therapeutics's Revenue

For the Biotechnology subindustry, Grace Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grace Therapeutics's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Grace Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Grace Therapeutics's Revenue falls into.



Grace Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Grace Therapeutics  (NAS:GRCE) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Grace Therapeutics Revenue Related Terms

Thank you for viewing the detailed overview of Grace Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Grace Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
103 Carnegie Center, Suite 300, Princeton, NJ, USA, 08540
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Executives
George Kottayil director 49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540
A Brian Davis director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Edward Neugeboren director 282 NEW NORWALK ROAD, NEW CANAAN CT 06840
Vimal Kavuru director 11 MAACKA DRIVE, HOLMDEL NJ 07733
Donald Olds director 545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3
Amresh Kumar officer: VP Program Management 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Carrie D'andrea officer: VP Clinical Operations 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
Prashant Kohli officer: Chief Executive Officer 206 CAMBRIDGE LANE, NEWTOWN PA 13940
R. Loch Macdonald officer: Chief Medical Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Michael Derby director 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
William A Haseltine director
Rajitha Grace 2018 Irrevocable Trust 10 percent owner 40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753
Swami Sambamurty Iyer 10 percent owner 20 TULSA COURT, MONMOUTH JUNCTION NJ 08852
Brian D. Ford officer: CHIEF FINANCIAL OFFICER 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5
John Canan director C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202